MedTrace Logo

Autologous Platelet Rich Plasma (PRP) Intra Ovarian Infusion in Perimenopausal Women

NCT03951194 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-12-24

No results posted yet for this study

Summary

Autologous PRP intra ovarian infusion may improve ovarian response and women's hormonal profile and may promote folliculogenesis in perimenopausal women.

Conditions

  • Infertility, Female
  • Perimenopausal Disorder
  • Menstrual Cycle Abnormal

Interventions

BIOLOGICAL

Autologous Platelet Rich Plasma (PRP) intra ovarian infusion

Autologous PRP intra ovarian infusion

OTHER

Placebo: Autologous Platelet Free Plasma (PFP) intra ovarian infusion

Autologous PFP intra ovarian infusion

Sponsors & Collaborators

  • National and Kapodistrian University of Athens

    collaborator OTHER

  • Genesis Athens Clinic

    lead OTHER

Principal Investigators

  • Agni Pantou, MD · Obstetrician Gynecologist

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-13
Primary Completion
2025-01-30
Completion
2025-07-30

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03951194 on ClinicalTrials.gov